Daniel Bourque is an Infectious Disease physician affiliated with Boston University. OpenAlex indexes 52 publications with 761 citations (h-index 17).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
725 Albany St, Ste 9b & C
Shapiro Bldg
Boston, MA 021182526
Telephone
617-414-4290Provider last certified this registry record 21 Jun 2023.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
34.5%Statin15.9%Atorvastatin Calcium52%Rosuvastatin Calcium48%Part D<11 patientsACE inhibitor6.1%Lisinopril63%Lisinopril-Hydrochlorothiazide37%Part D<11 patients+ 5 more classes in this area
Anti-infectives
32.4%Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor9%Tivicay81%Juluca19%Part D<11 patientsAntimycobacterial7%Isoniazid62%Ethambutol Hcl38%Part D<11 patients+ 5 more classes in this area
Metabolism & gastrointestinal
11.5%Biguanide (metformin)5.4%Metformin Hcl71%Metformin Hcl Er29%Part D<11 patientsGLP-1 receptor agonist2.2%Trulicity100%Part D<11 patients+ 2 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Barriers to Chagas Disease Screening among Primary Care Providers in the United States
American Journal of Tropical Medicine and Hygiene
2026 - Rifampin versus isoniazid completion rates for TB infection
The International Journal of Tuberculosis and Lung Disease
2025 - P-899. Strong Hearts Program: Results of a Novel Primary-Care Based Chagas Disease Care Program in East Boston, MA, 2017-2023
Open Forum Infectious Diseases
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Michael Holick, MD
Boston University
Gene Kwan, MD
Boston University
Joseph Antin, MD
Boston University
George O'Connor, MD
Boston University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”